A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Dapagliflozin (FARXIGA)

SGLT2 Inhibitor (Antidiabetic) class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2008-01-14
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$11.48/unit
7 NDCs benchmarked, lowest of all strengths.
Average NADAC
$11.91
Across all dosage forms in distribution.
Highest NADAC
$12.08
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Dapagliflozin used for?

Dapagliflozin is a SGLT2 Inhibitor (Antidiabetic) medication tracked in Medicare Part D.

Is there a generic for Dapagliflozin?

No. Dapagliflozin is brand-only with no generic equivalents currently in market.

How much does my plan pay for Dapagliflozin?

Across 329 Part D plans, Dapagliflozin averages $11.91/unit (NADAC). Lowest available: $11.48/unit. Highest in distribution: $12.08/unit.

Is Dapagliflozin on the FDA shortage list?

No. Dapagliflozin is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

SGLT2 Inhibitor (Antidiabetic)1 alternative in D1
01
Canagliflozin
Brand: INVOKANA
$19.11Lowest NADAC
0Generic mfrs
$364.8MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (7 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.